Short-term Results of SuperPATH Versus Direct Lateral Approach In Primary Total Hip Arthroplasty: A Randomized Controlled Study.

June 5, 2026 updated by: Islam Mohamed Abd El Hameed, Assiut University

Total hip arthroplasty (THA) has shown great success in relieving joint pain and disability and has been a procedure of choice for the treatment of end-stage degenerative joint diseases and trauma.

There are multiple surgical approaches for THA, including the traditional posterior approach, anterior approach, lateral approach, anterolateral approach and posterolateral approach; each has its advantages and complications.

Modified direct lateral approach is considered as standard, most commonly used and familiar in Assiut university Arthroplasty centre. Yet it may cause abductor weakness, post operative pain, prolonged rehabilitation time and more blood loss.

In the past two decades, the group of micro-posterior approaches was introduced. In 2004 Stephen Murphy developed the Supecapsular (SuperCap) approach, preparing the hip insitu to reduce soft tissue traumatization caused by the dislocation manoeuvre used in the conventional posterior approach. , In 2008 Brad Penenberg developed the percutaneously-assisted total hip (PATH) app, a tissue-sparing approach leading through the interval between gluteus medius and the conjoined tendon of the external rotators.

In2011, James Chow described the supercapsular percutaneously-assisted total hip (SuperPATH) approach, the most Important features of SuperPATH are the following: (a) muscle sparing between gluteus medius and piriformis without detaching external rotator tendons or disrupting the hip capsule, (b) femur preparation first without dislocation (c) percutaneous acetabular preparation.

SuperPATH approach is designed to reduce soft tissue trauma and so blood loss, post operative pain, improve joint stability and allow earlier mobilization of patients.

Despite the theoretical advantages of the SuperPATH approach, its adoption remains limited compared with conventional surgical approaches. Furthermore, there is ongoing debate regarding its clinical superiority in terms of functional outcomes, complication rates and implant position.

Aim of our study is to evaluate the clinical and functional outcomes of total hip arthroplasty performed using SuperPATH compared to modified direct lateral approach.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Mohamed Mostafa Alaa eldin and el aziz, Assistant professor
  • Phone Number: 0201096967747
  • Email: Mohamed.m.alaa@aun.edu.eg

Study Locations

    • Asyut Governorate
      • Asyut, Asyut Governorate, Egypt
        • Assiut University hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Primary total hip arthroplasty.
  2. Age > 18 years.
  3. Body mass index < 40 kg/m2.
  4. Able to ambulate preoperative.

Exclusion Criteria:

  1. Hip deformity (acetabular or femoral).
  2. Ankylosed hips.
  3. Severe osteoporosis.
  4. Neuromuscular disorders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Direct lateral approach
total hip arthroplasty via direct lateral approach
Direct lateral approach is approach through the intra muscular septum of gluteus medial muscle SuperPATH approach is minimally invasive posterolateral approach for the hip
Experimental: SuperPATH
This arm will include patients who will undergo total hip arthroplasty via SuperPATH approach
Direct lateral approach is approach through the intra muscular septum of gluteus medial muscle SuperPATH approach is minimally invasive posterolateral approach for the hip

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Harris hip score
Time Frame: Immediately post operative 3 months 6 months One year Two years
Immediately post operative 3 months 6 months One year Two years

Secondary Outcome Measures

Outcome Measure
Time Frame
Oxford hip score
Time Frame: Immediately post operative 3 months 6 months One year Two years
Immediately post operative 3 months 6 months One year Two years
Visual analogue score
Time Frame: Immediately post operative 3 months 6 months One year Two years
Immediately post operative 3 months 6 months One year Two years
Operative time in minutes
Time Frame: Duration of the operation
Duration of the operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

May 30, 2026

First Submitted That Met QC Criteria

June 5, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 5, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ORTHO-2026-015

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Compare Two Surgical Approaches Used in Total Hip Arthroplasty

Clinical Trials on Surgical approaches: direct lateral approach for the hip and SuperPATH approach

Subscribe